StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
071200.KQ$7240.00-4.99%
Fair $7240.00+0.0%

071200.KQ

INFINITT Healthcare Co., Ltd.

Unknown / UnknownKOSDAQ

$7240.00

-380.00 (-4.99%)

Fairly Valued+0.0%Fair Value $7240.00Fund rank 36/100 · Data gapFallback financials|
SA 62/B
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $11.5B · quality 79.3/100

Data gap 36/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 78/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

62/100

B

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 071200.KQLocal privado en este navegador · INFINITT Healthcare Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$176.5B

P/E

6.7x

↓

EV/EBITDA

4.2x

↓

ROE

13.8%

↑

Gross Margin

61.5%

↑

Debt/Equity

0.01

↓
52-Week Range$7240
$5250$9180

TradingView lightweight chart

071200.KQ price, volumen y niveles de valoración

Último $7,240Periodo +43.4%
Fair value: $7,240

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+5.1%

FCF CAGR

+17.2%

FCF margin

12.9%

FCF / Net income

0.50x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $102.39B · net income $26.40B · FCF $13.26B

2022-FY → 2025-FY

Gross margin

61.5%-0.0% pts

Operating margin

13.9%+5.0% pts

Net margin

25.8%+25.6% pts

FCF margin

12.9%+3.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$102.39B$102.39B$95.75B$85.86B$88.29B
Net Income$26.40B$26.40B$37.80B$16.46B$131.6M
EBITDA$37.78B$37.78B$50.80B$24.21B$-412.9M
EPS1083.001083.001550.00675.005.00
Gross Margin61.5%61.5%61.3%58.4%61.5%
Operating Margin13.9%13.9%8.1%4.6%8.9%
Net Margin25.8%25.8%39.5%19.2%0.1%
Balance Sheet
Debt/Equity0.010.010.020.030.04
Cash Flow
Free Cash Flow$13.26B$13.26B$11.46B$9.50B$8.23B
Returns
ROE13.8%13.8%22.4%12.5%0.1%
Valuation
P/E6.696.692.697.691124.00
EV/EBITDA4.224.221.784.82—
P/B0.920.920.600.961.28
Growth & Yield
Revenue Growth6.9%6.9%11.5%-2.7%—
EPS Growth-30.1%-30.1%129.6%13400.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-16.0%

fácil

EPS terminal req.

$642.43

Spread vs growth

-14.2%

5Y implied EPS CAGR

-6.4%

fácil

EPS terminal req.

$777.34

Spread vs growth

-23.7%

10Y implied EPS CAGR

1.5%

fácil

EPS terminal req.

$1251.91

Spread vs growth

-31.6%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +20.7%

Total return

+20.7%

Start / end P/E

3.9x → 6.7x

EPS bridge

1550.00 → 1083.00

Residual

-21.9%

EPS growth-30.1%
Multiple rerating+72.7%
Dividend+0.0%
Residual / FX / buybacks / cross-term-21.9%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.